A recently published meta‐analysis consisting of randomized controlled trials involving patients with HFpEF revealed that β‐blockers, ACEI, ARB, and mineralocorticoid receptor antagonists treatment has little or no effect on all‐cause mortality, and β‐blockers maybe have a possible reduction in cardiovascular mortality, mineralocorticoid receptor antagonists probably reduces HF hospitalization, and other drugs have no observed benefits for cardiovascular mortality and heart hospitalization.42 This evidence concerns the gene NR3C2 and hydrops fetalis.